ProQR Therapeutics price target raised to $10 from $5 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on ProQR Therapeutics (PRQR) to $10 from $5 and keeps a Buy rating on the shares. The firm says that as AX-0810 gets closer to the clinic, it now includes AX-0810 in its valuation and estimates an initial launch revenue of $29M in 2028 growing to $362M in 2034.